Follow
Daniel Kwon
Daniel Kwon
University of Ottawa
Verified email at toh.ca
Title
Cited by
Cited by
Year
Development of a direct photocatalytic C–H fluorination for the preparative synthesis of odanacatib
SD Halperin, D Kwon, M Holmes, EL Regalado, LC Campeau, ...
Organic letters 17 (21), 5200-5203, 2015
1752015
Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation
BJ Fraser, S Beldar, A Seitova, A Hutchinson, D Mannar, Y Li, D Kwon, ...
Nature chemical biology 18 (9), 963-971, 2022
992022
Insight into the Development of PET Radiopharmaceuticals for Oncology
J Lau, E Rousseau, D Kwon, KS Lin, F Bénard, X Chen
Cancers 12 (5), 1312, 2020
682020
Positron emission tomography imaging of the gastrin-releasing peptide receptor with a novel bombesin analogue
J Lau, E Rousseau, Z Zhang, CF Uribe, HT Kuo, J Zeisler, C Zhang, ...
ACS omega 4 (1), 1470-1478, 2019
322019
A systematic review of molecular imaging agents targeting bradykinin B1 and B2 receptors
J Lau, J Rousseau, D Kwon, F Bénard, KS Lin
Pharmaceuticals 13 (8), 199, 2020
302020
Total Synthesis of Amphirionin-4
M Holmes, D Kwon, M Taron, R Britton
Organic letters 17 (15), 3868-3871, 2015
262015
High-Contrast CXCR4-Targeted 18F-PET Imaging Using a Potent and Selective Antagonist
D Kwon, J Lozada, Z Zhang, J Zeisler, R Poon, C Zhang, A Roxin, KS Lin, ...
Molecular Pharmaceutics 18 (1), 187-197, 2020
222020
Structure, activity and inhibition of human TMPRSS2, a protease implicated in SARS-CoV-2 activation
BJ Fraser, S Beldar, A Seitova, A Hutchinson, D Mannar, Y Li, D Kwon, ...
BioRxiv, 2021.06. 23.449282, 2021
202021
Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma
K Takata, LC Chong, D Ennishi, T Aoki, MY Li, A Thakur, S Healy, ...
The Journal of Clinical Investigation 132 (10), 2022
182022
[68Ga]Ga/[177Lu]Lu-BL01, a Novel Theranostic Pair for Targeting C-X-C Chemokine Receptor 4
J Lau, D Kwon, E Rousseau, Z Zhang, J Zeisler, CF Uribe, HT Kuo, ...
Molecular Pharmaceutics 16 (11), 4688-4695, 2019
182019
Comparison of biological properties of [177Lu]Lu‐ProBOMB1 and [177Lu]Lu‐NeoBOMB1 for GRPR targeting
E Rousseau, J Lau, Z Zhang, C Zhang, D Kwon, CF Uribe, HT Kuo, ...
Journal of Labelled Compounds and Radiopharmaceuticals 63 (2), 56-64, 2020
112020
Synthesis and evaluation of an 18F‐labeled trifluoroborate derivative of 2‐nitroimidazole for imaging tumor hypoxia with positron emission tomography
PSG Nunes, Z Zhang, HT Kuo, C Zhang, J Rousseau, E Rousseau, J Lau, ...
Journal of Labelled Compounds and Radiopharmaceuticals 61 (4), 370-379, 2018
112018
Total synthesis of biselide A
VR Challa, D Kwon, M Taron, H Fan, B Kang, D Wilson, FPJ Haeckl, ...
Chemical Science 12 (15), 5534-5543, 2021
82021
Targeting refractory mantle cell lymphoma for imaging and therapy using CXC chemokine receptor type 4 radioligands
D Kwon, K Takata, Z Zhang, L Chong, B Fraser, J Zeisler, T Miyata-Takata, ...
Clinical Cancer Research 28 (8), 1628-1639, 2022
62022
Reducing the kidney uptake of high contrast CXCR4 PET imaging agents via linker modifications
D Kwon, Z Zhang, J Zeisler, HT Kuo, KS Lin, F Benard
Pharmaceutics 14 (7), 1502, 2022
42022
Novel cxcr4-targeting compounds
F Bénard, K Lin, Z Zhang, K Daniel, D Perrin, M Todorovic, J Lozada, ...
US Patent App. 18/032,680, 2024
2024
Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy
F Bénard, K Lin, E Rousseau, Z Zhang, K Daniel, J Lau, CU Munoz, ...
US Patent App. 17/604,708, 2022
2022
The system can't perform the operation now. Try again later.
Articles 1–17